View Schedule

Wednesday, Nov. 11, 2020 

Pre-Conference Program

8 a.m.–5 p.m.
Riverview Ballroom (A,1,2,3)

Primer on Tumor Immunology and Cancer Immunotherapy™

8 a.m.

TBA

8 a.m.–5 p.m.
Riverview Ballroom (B,4,5) 

Engineering Immune Cells for Cancer Therapy 

8 a.m. Introduction

Session I: Advances in Adoptive T cell Therapy for Cancer: TILs and TCRs

8:05 a.m.

Neoantigen-expanded T cells/TCRs

8:30 a.m.

TILs
John Haanen, MD, PhD – Netherlands Cancer Institute

8:55 a.m.

Endogenous T cells
Cassian Yee, MD – The University of Texas MD Anderson Cancer Center

9:20 a.m.

Session I Panel Discussion

9:55 a.m.

Break

Session II: Novel Approaches to Enhance CAR T cell Therapy

10:15 a.m.

Next-generation CARs for blood cancers

10:40 a.m.

CAR for solid tumors
Saul Priceman, PhD – City of Hope

11:05 a.m.

Resistance and next-generation approaches 
Marco Ruella, MD – University of Pennsylvania

11:30 a.m.

Session II Panel Discussion 

12:05 p.m.

Lunch

Session III: CAR-Based Strategies Beyond T Lymphocytes
1:05 p.m.

NK cells
Katayoun Rezvani, MD, PhD – The University of Texas MD Anderson Cancer Center

1:30 p.m.

Macrophages
Michael Klichinsky, PharmD, PhD – Carisma Therapeutics

1:55 p.m.

B cells
Justin Taylor, PhD – Fred Hutchinson Cancer Research Center

2:20 p.m.

Session III Panel Discussion

2:55 p.m.

Break

Session IV: Integration of Novel Technologies for CAR Therapy and their Translation to the Clinic
3:10 p.m.

Novel concepts in manufacturing
Isabelle
Rivière, PhD – Memorial Sloan Kettering Cancer Center

3:35 p.m.

Off-the-shelf, including allogeneic and iPSCs
Barbra Sasu, PhD – Allogene Therapeutics

4 p.m.

Genetic engineering and novel approaches
Carl June, MD – University of Pennsylvania

4:25 p.m.

Session IV Panel Discussion

Session: The Surgeon's Impact on Tumor Immunotherapy: Recent Achievements and Future Promise
Riverview Ballroom
Co-Chairs:
Brian R. Gastman, MD – Cleveland Clinic Cancer Center
Howard L. Kaufman, MD, FACS Immuneering Corporation

5:30 p.m.

Microbiome

5:40 p.m.

Oncolytic Viruses
Howard L. Kaufman, MD, FACS – Immuneering Corporation

5:50 p.m.

Abstract

5:55 p.m.

Abstract

6 p.m.

Abstract

6:05 p.m.

Abstract

6:10 p.m.

Expert Discussant

6:20 p.m.

Q&A
 

Grant Writing Workshop

Wednesday, Nov. 11, 2020

Annual Meeting

5:30–6:30 p.m.

The Surgeon's Impact on Tumor Immunotherapy: Recent Achievements and Future Promise
Riverview Ballroom A/1-3
Co-Chairs:
Brian R. Gastman, MD – Cleveland Clinic Cancer Center

Howard L. Kaufman, MD, FACS – Immuneering Corporation

5:30 p.m

Microbiome

5:40 p.m.

Oncolytic Viruses
Howard L. Kaufman, MD, FACS – Immuneering Corporation

5:50 p.m. Abstract
5:55 p.m. Abstract
6 p.m. Abstract
6:05 p.m. Abstract
6:10 p.m. Expert Discussant
6:20 p.m. Q&A

Thursday, Nov. 12, 2020

Annual Meeting

8 a.m.–8:30 p.m.

Presidential Welcome
Potomac Ballroom

8 a.m.

Mario Sznol, MD – Yale School of Medicine

Session 100: Update Session
Potomac Ballroom

8:05 a.m.

TBA

Session 101: Richard V. Smalley, MD Memorial Award and Lectureship
Potomac Ballroom

8:35 a.m.

The PD-L1/PD-1 Pathway: Discovery and New Insights
Gordon Freeman, PhD – Dana-Farber Cancer Institute

9:05 a.m.

Why Were We Interested in Immunity Within the Tumor Microenvironment in the 1990s?
Lieping Chen, MD, PhD – Yale School of Medicine

9:35 a.m.

Discovery of New IO Targets and Mechanisms Leveraging CRISPR
Arlene Sharpe, MD, PhD – Harvard Medical School

Session 102: Combinatorial Therapies
Potomac Ballroom
Co-Chairs:
Charlotte E. Ariyan, MD, PhD – Memorial Sloan Kettering Cancer Center
Silvia Formenti, MD Weill Cornell Medicine

10:05 a.m.

TBA

Session 103: Late-Breaking Abstract Session
Potomac Ballroom

12 p.m.

Abstract

12:15 p.m.

Abstract

Lunch & Poster Viewing
Prince George Exhibit Hall

12:30–2 p.m.



Session 104: NCI Session on Integrating Radiation and Immunotherapy
National Harbor 2-3

12:30 p.m.

TBA

Meet-the-Expert Lunch
Chesapeake 456

12:45–2 p.m.



Session 105: Toxicities
Potomac Ballroom
Co-Chairs:
Caroline Robert, MD, PhD – Institut Gustave Roussy
Cameron J. Turtle, MBBS, PhD, FRACP – Fred Hutchinson Cancer Research Center

2 p.m.

TBA

3:45–4:15 p.m.

Break

Concurrent Session 106: Developing Cellular Therapies for Solid Cancers
Potomac Ballroom AB
Co-Chairs:
Stephanie L. Goff, MD, FACS – National Cancer Institute
Avery Posey, PhD – University of Pennsylvania School of Medicine

4:15 p.m.

TILS

4:35 p.m.

TCR Cells
James C. Yang, MD – National Cancer Institute

4:55 p.m.

CAR for Solid Tumors
Avery Posey, PhD – University of Pennsylvania School of Medicine

5:15 p.m.

NKT Cells
Andras A. Heczey, MD – Baylor College of Medicine

5:35 p.m.

Abstract

Concurrent Session 107: Neoadjuvant Immunotherapies
Potomac Ballroom CD, 1-6
Co-Chairs:
Padmanee Sharma, MD, PhD – The University of Texas MD Anderson Cancer Center
Janis M. Taube, MD, MSc – Johns Hopkins School of Medicine

4:15 p.m.

Pan-Tumor Pathologic Response Assessment
Janis M. Taube, MD, MSc – Johns Hopkins School of Medicine

4:35 p.m.

Neoadjuvant Breast Cancer
Elizabeth A. Mittendorf, MD, PhD – Dana-Farber Cancer Institute Brigham & Woman's Cancer Institute

4:55 p.m.

Bladder Cancer
Jianjun Gao, MD, PhD – The University of Texas MD Anderson Cancer Center

5:15 p.m.

Abstract

5:30 p.m.

Abstract

Concurrent Session 108: Diet and Microbiome
Cherry Blossom Ballroom
Co-Chairs:
Jeremiah Faith, PhD – Icahn Institute for Data Science and Genomic Technology at Mt. Sinai
Laurence Zitvogel, MD, PhD – Institut Gustave Roussy

4:15 p.m.

TBA

Concurrent Session 109: Innate Immunity: The Next Generation of Targets for Anti-Cancer Immunotherapy
National Harbor 2-3
Co-Chairs:
Jennifer L. Guerriero, PhD – Dana-Farber Cancer Institute
Katayoun Rezvani, MD, PhD – The University of Texas MD Anderson Cancer Center

4:15 p.m.

Tumor-Associated Macrophages
Jennifer L. Guerriero, PhD – Dana-Farber Cancer Institute

4:35 p.m.

Gamma-delta T cells
Adrian Hayday, FRS, F MedSci – Gamma Delta Therapeutics

4:55 p.m.

NK Cells
Andreas Lundqvist, PhD – Karolinska Institutet

5:15 p.m.

Abstract

5:30 p.m.

Abstract

Session 110: Poster Symposium
Potomac Ballroom CD, 1-6

5:45 p.m.

 

Poster Reception
Prince George Exhibit Hall

7–8:30 p.m.

 

Career Connections Networking Reception
TBD

8:30–9:30 p.m.

 

Friday, Nov. 13, 2020

Annual Meeting

8 a.m.–8:30 p.m.

Organizer Welcome
Potomac Ballroom

8 a.m.

TBA

Session 200: Update Session
Potomac Ballroom

8:05 a.m.

TBA

Session 201: Keynote Address
Potomac Ballroom
Chair:
Mario Sznol, MD – Yale School of Medicine

9:05 a.m.

Introduction
Mario Sznol, MD – Yale School of Medicine

9:10 a.m.

Turning Immunologically Quiescent Tumors into Immune Responsive Cancers
Elizabeth M. Jaffee, MD – Sidney Kimmel Cancer Center, Johns Hopkins University

9:50 a.m.

Q&A
Elizabeth M. Jaffee, MD – Sidney Kimmel Cancer Center, Johns Hopkins University

Session 202: Cold Tumor Microenvironment
Potomac Ballroom
Co-Chairs:
Vincenzo Bronte, MD – University of Verona
Miriam Merad, MD, PhD – Icahn School of Medicine at Mount Sinai

9:55 a.m.

TBA

Session 203: Late-Breaking Abstract Session
Potomac Ballroom

11:50 a.m.

Abstract

12:05 p.m.

Abstract

Session 204: Update Session
Potomac Ballroom

12:20 p.m.

TBA

Lunch & Poster Viewing
Prince George
Exhibit Hall

12:35–2:05 p.m.



Concurrent Rapid Oral Abstract Presentation Session 205: Basic Research
TBD

12:50 p.m.

Abstract

12:58 p.m.

Abstract

1:06 p.m.

Abstract

1:14 p.m.

Q&A

1:20 p.m.

Abstract

1:28 p.m.

Abstract

1:36 p.m.

Abstract

1:44 p.m.

Q&A

Concurrent Rapid Oral Abstract Presentation Session 206: Clinical
TBD

12:50 p.m.

Abstract

12:58 p.m.

Abstract

1:06 p.m.

Abstract

1:14 p.m.

Q&A

1:20 p.m.

Abstract

1:28 p.m.

Abstract

1:36 p.m.

Abstract

1:44 p.m.

Q&A

Session 207: Presidential Session
Potomac Ballroom
Chair:
Mario Sznol, MD – Yale School of Medicine

2:05 p.m.

Introduction
Mario Sznol, MD – Yale School of Medicine

2:10 p.m.

Abstract

2:25 p.m.

Abstract

2:40 p.m.

Expert Discussant

2:50 p.m.

Abstract

3:05 p.m.

Abstract

3:20 p.m.

Expert Discussant

3:30–3:45 p.m.

Break

Concurrent Session 208: Vaccines and Immunoprevention
Potomac Ballroom AB
Co-Chairs:
Shizuko Sei, MD – National Cancer Institute
Catherine J. Wu, MD – Dana-Farber Cancer Institute

3:45 p.m.

Tumor Immune Surveillance

4:10 p.m.

Antigen selection for Cancer Vaccines
Catherine J. Wu, MD – Dana-Farber Cancer Institute

4:35 p.m.

Cancer Vaccines for Lynch Syndrome Carrier
Eduardo Vilar-Sanchez, MD, PhD  The University of Texas MD Anderson Cancer Center

5 p.m.

Abstract

Concurrent Session 209: Gene Editing
Potomac Ballroom CD, 1-6
Co-Chairs:
Helen E. Heslop, MD – Baylor College of Medicine
Carl H. June, MD – University of Pennsylvania

3:45–5:15 p.m.

Panelist

 

Panelist

 

Panelist

 

Panelist

 

Panelist

 

Panelist

Concurrent Session 210: Cytokines and Bispecifics
Cherry Blossom Ballroom
Co-Chairs:
Dimitris Skokos, PhD – Regeneron Pharmaceuticals, Inc.
Mario Sznol, MD – Yale School of Medicine

3:45 p.m.

TBA

Concurrent Session 211: Immunometabolism and ICI Resistance
National Harbor 2-3
Co-Chairs:
Susan M. Kaech, PhD – Salk Institute
Maxim N. Artyomov, PhD – Washington University School of Medicine in St. Louis

3:45 p.m.

Metabolic Regulation of Anti-Tumor NK cells

4:10 p.m.

Metabolic Processes that Affect Anti-Tumor Immune Responses
Santosh Vardhana, MD, PhD – Memorial Sloan Kettering Cancer Center

4:35 p.m.

Energizing Anti-Tumor T cell Responses via Glutamine Metabolism
Jonathan D. Powell, MD, PhD – Johns Hopkins Medicine

5 p.m.

Abstract

5:15 – 5:30 p.m.

Break

Concurrent Session 212: Novel immunotherapies in myeloid malignancies
Potomac Ballroom AB
Co-Chairs:
Naval Daver, MD – The University of Texas MD Anderson Cancer Center
Marcela V. Maus, MD, PhD – Massachusetts General Hosptial

5:30 p.m.

CD47 Macrophage Checkpoint-Based Immunotherapy (Lymphomas, MDS, AML)
David Sallman, MD  Moffitt Cancer Center

5:50 p.m.

Bispecific Antibodies
Marion Subklewe, MD – University of Munich

6:10 p.m.

CAR T for AML
Elizabeth Budde, MD, PhD – City of Hope

6:30 p.m.

Abstract

6:45 p.m.

Abstract

Concurrent Session 213: Reverse Translation for Clinical Trials
Potomac Ballroom CD, 1-6
Co-Chairs:
Matthew Galsky, MD – Tisch Cancer Institute at Mount Sinai Medical Center
Padmanee Sharma, MD, PhD
 – The University of Texas MD Anderson Cancer Center

5:30 p.m.

Abstract

5:45 p.m.

Abstract

6 p.m.

Abstract

6:15 p.m.

Abstract

6:30 p.m.

Abstract

6:45 p.m.

Abstract

Concurrent Session 214: Engineering Immunity: Biomolecular and Genetic Approaches to Generating Novel Therapeutic Function
Cherry Blossom Ballroom
Co-Chairs:
Yvonne Chen, PhD – University of California, Los Angeles
Kole T. Roybal, PhD – University of California, San Francisco

5:30 p.m.

Biomaterials – Basic Biology
Jennifer H. Elisseeeff, PhD – Johns Hopkins School of Medicine

5:55 p.m.

Biomaterials – Immunotherapy
Darrell J. Irvine, PhD – MIT

6:20 p.m.

Gene Editing

6:45 p.m.

Abstract

Concurrent Session 215: B Cells
National Harbor 2-3
Co-Chairs:
Tullia Bruno, PhD – UPMC Hillman Cancer Center
Wolf Fridman, MD, PhD – Cordeliers Research Centre

5:30 p.m.

TBA

Poster Reception
Prince George Exhibit Hall

7–8:30 p.m.

 

The CheckPoints Band Party
Riverview Ballroom

9–11 p.m.

 

Saturday, Nov. 14, 2020

Annual Meeting

8 a.m.–6:30 p.m.

Organizer Welcome
Potomac Ballroom

8 a.m.

TBA

Session 300: Update Session
Potomac Ballroom

8:05 a.m.

SITC Business Meeting

Session 301: 35th Anniversary Keynote Address
Potomac Ballroom
Chair:
Mario Sznol, MD – Yale School of Medicine

9:05 a.m.

Introduction
Mario Sznol, MD – Yale School of Medicine

9:10 a.m.

T cell Therapy of Cancer
Helen E. Heslop, MD – Baylor College of Medicine

9:50 a.m.

Q&A
Helen E. Heslop, MD – Baylor College of Medicine

Session 302: Biomarkers and Big Data
Potomac Ballroom
Co-Chairs:
Michael Angelo, MD, PhD – Stanford University
Nir Hacohen, PhD – Broad Institute

9:55 a.m.

TBA

Session 303: Late-Breaking Abstract Session
Potomac Ballroom

11:50 a.m.

Abstract

12:05 p.m.

Abstract

Lunch

12:20–1:50 p.m.



Concurrent Rapid Oral Abstract Presentation Session 304: Basic Research
TBD

12:35 p.m.

Abstract

12:43 p.m.

Abstract

12:51 p.m.

Abstract

12:59 p.m.

Q&A

1:05 p.m.

Abstract

1:13 p.m.

Abstract

1:21 p.m.

Abstract

1:29 p.m.

Q&A

Concurrent Rapid Oral Abstract Presentation Session 305: Clinical
TBD

12:35 p.m.

Abstract

12:43 p.m.

Abstract

12:51 p.m.

Abstract

12:59 p.m.

Q&A

1:05 p.m.

Abstract

1:13 p.m.

Abstract

1:21 p.m.

Abstract

1:29 p.m.

Q&A

Session 306: Hot Topic Symposium
Potomac Ballroom

1:50 p.m.

TBA

3:45–4 p.m.

Break

Awards Ceremony
Potomac Ballroom
Chair:

Mario Sznol, MD – Yale School of Medicine

4–5 p.m.

 

Session 307: 35th Anniversary Session: Mechanistic Understandings and Misunderstandings
Potomac Ballroom

Co-Chairs:
James P. Allison, PhD – The University of Texas MD Anderson Cancer Center
John Wherry, PhD – University of Pennsylvania

5 p.m.

TBA

35th Anniversary Reception
National Museum of American History

7–10 p.m.

 

Sunday, Nov. 15, 2020

Annual Meeting

8–10 a.m.

Next Generation ImmunoOncology Combinations: FDA, Clinical Trial Designs, Diagnostics and Biomarkers
Cherry Blossom Ballroom

8 a.m.

TBA

Schedule At-a-Glance

Tuesday, Nov. 10
Pre-Conference Programs
(Additional Fees Required)

Immunotherapy Resistance and Failure

Wednesday, Nov. 11
Pre-Conference Programs
(Additional Fees Required)

Primer on Tumor Immunology and Cancer Immunotherapy™

Social Activity:
Early Career Scientist Networking Reception

Workshop on Engineering Immune Cells for Cancer Therapy

Grant Writing Workshop
Thursday, Nov. 12
Annual Meeting

35th Anniversary Annual Meeting

Social Activity:
Poster Reception
Career Connections Networking Reception

Meet-the-Expert Lunch

Friday, Nov. 13
Annual Meeting

35th Anniversary Annual Meeting

Social Activities:
Poster Reception
The CheckPoints Party

Saturday, Nov. 14
Annual Meeting


35th Anniversary Annual Meeting

Social Activity:
35th Anniversary Reception
(Additional Fees Required)

35th Anniversary Keynote Address

35th Anniversary Session: Mechanistic Understandings and Misunderstandings

Sunday, Nov. 15
Annual Meeting

Next Generation ImmunoOncology Combinations: FDA, Clinical Trial Designs, Diagnostics and Biomarkers